Under State Council preferential mandates, Yiling provides immediate clinical access to leading-edge pharmaceuticals and devices plus expedited foreign physician licensing — concurrent with FDA and EMA approvals.
Enacted by the State Council to bridge the multi-year regulatory lag between global innovation and domestic patient access.
Innovative drugs, targeted oncology therapies and robotic surgical consoles approved by the FDA, EMA or PMDA can be imported and administered in Boao Lecheng ahead of domestic registration cycles.
3–7 working days for urgent cases
Oncology, rare diseases, cardiovascular, aesthetics
Foreign licensed specialists receive multi-year clinical operating rights through streamlined credential validation — enabling transnational MDT surgeries and direct patient interventions.
3-year renewable, multi-site
Collaborative inpatient surgeries allowed
Medical equipment and biological agents imported into the zone benefit from zero-tariff and bonded warehousing under Free Trade Port statutes — lowering therapeutic overheads for patients.
Zero-tariff list for medical devices
Air-side clearance at −80 °C / LN2
Clinical outcomes from treatments performed in the zone are compiled under standardized protocols into Real-World Evidence, formally accepted by the NMPA to expedite national registration.
Accepted for NMPA drug & device filing
Dual-tier ethics review & tele-monitoring
Since the zone opened, Yiling has established tertiary diagnostic centers, biotherapy suites and international collaboration hubs inside Boao.
International-standard inpatient pavilions, laminar-flow surgical suites, hyperbaric oxygen chambers and longevity laboratories across 166,000 square meters.
End-to-end temperature monitoring from the manufacturing facility to the patient administration bed.
Direct academic leadership from academy fellows and longevity researchers for complex case management.
Active approvals covering next-generation analogues, bispecific oncology antibodies and biologic cell therapies.
A four-stage administrative mechanism for transparency, regulatory compliance, ethics verification and patient safety.
Clinical history, pathology reports and imaging are reviewed by the bilingual intake team for therapeutic qualification.
Requirement · Full medical summary with verified indication within 48 hours.
Hospital ethics review and submission to the Boao Lecheng administration for the designated drug or device approval.
Turnaround · Expedited statutory clearance in 3–5 working days.
The official medical invitation letter enables 59-nation visa-free entry or a fast-tracked medical visa.
Logistics · Meet-and-greet pickup at Haikou (HAK) or Sanya (SYX).
Admission, precision administration, digital real-world monitoring, then transnational follow-up.
Follow-up · Multilingual tele-health consults at 30, 90 & 180 days.
Connected modules across the Yiling international healthcare ecosystem.
Frontier drugs and devices available inside the Boao Lecheng pilot zone only.
Open sectionPolicy timeline and key points of the pilot zone.
Open sectionHainan visa-free countries and our invitation-letter service.
Open sectionSubmit preliminary diagnostics for case triage by our ethics committee and medical liaison board — confidential under GL-02 statutory privacy protocols, with no fee for the preliminary review.
Import and use of foreign-approved clinical assets are governed by Decree No. [2013] 33 and Hainan provincial regulatory measures; all dosing is supervised inside pilot-zone institutions.
International patient records comply with GL-02 data-residency requirements while enabling encrypted sharing with referring overseas physicians.
Direct billing accords with global insurers and third-party administrators, with multi-currency accounts and mediated dispute resolution on campus.
